Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT06323226
Recruiting Observational

The Impact of Sepsis on Long-term Outcomes in Critical Ill Children With Sepsis

NCT06323226 · tracked via the Priya Life Science China tracker
Sponsor
West China Hospital
Phase
Observational
Started
2019-01-01
Last updated
2026-01-22

Condition(s) studied

SepsisChildren, Only

Study summary

This study is conducted in critically ill children with sepsis with a five years follow-up. We aim to investigate the impact of sepsis on long-term outcomes including growth, neurodevelopment, survival rate, quality of life.

Eligibility

Sex
ALL
Min age
0 Years
Max age
16 Years
Healthy volunteers
No
Inclusion Criteria: We included critically ill children with sepsis who successfully discharged from pediatric Intensive care units, age \< 16 years. We also included age, sex, illness severity matched critically ill children as control group. Exclusion Criteria: We excluded children with underlying diseases, cancer, hematologic malignancy.

Primary outcome measure(s)

  • Mortality — Five years
    Rate of death in 5-years follow-up

Trial sites (1)

FacilityCityRegionStatus
West China Hospital of Sichuan University Chengdu Sichuan Recruiting

More West China Hospital trials in China

DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors Recruiting
Gamified Neurology Grand Rounds Active, not recruiting
Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection Recruiting
Assessment System for Sarcopenia Based on Ultrasonographic Data Recruiting
Tai Chi for Cancer-Related Fatigue During Radiotherapy in Patients With Head and Neck Cancer Recruiting

Other trials for the same condition

Immune Evaluation for Postoperative Sepsis-AKI Enrolling by invitation
Transcutaneous Auricular Vagus Nerve Stimulation as Adjuvant Treatment for Sepsis Patients Recruiting
Detection of Sepsis Occurrence by Using Blood Fluorescence Recruiting
Xuanbai Yiqi Decoction for Sepsis: A Randomized Controlled Trial Starting soon
Evidence-based Evaluation and Mechanism of Shenhuang Granules in the Treatment of Sepsis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06323226 on ClinicalTrials.gov ↗ ← All trials in China